US4282202A - Intramammary compositions - Google Patents
Intramammary compositions Download PDFInfo
- Publication number
- US4282202A US4282202A US06/088,859 US8885979A US4282202A US 4282202 A US4282202 A US 4282202A US 8885979 A US8885979 A US 8885979A US 4282202 A US4282202 A US 4282202A
- Authority
- US
- United States
- Prior art keywords
- sodium
- composition
- amoxycillin
- molecular sieve
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000002808 molecular sieve Substances 0.000 claims abstract description 24
- 239000000725 suspension Substances 0.000 claims abstract description 19
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical class OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 34
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 15
- 229910052708 sodium Inorganic materials 0.000 claims description 15
- 239000011734 sodium Substances 0.000 claims description 14
- 229960003022 amoxicillin Drugs 0.000 claims description 13
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 13
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims description 9
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 7
- 229930182555 Penicillin Natural products 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229960003324 clavulanic acid Drugs 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229930186147 Cephalosporin Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 229940124587 cephalosporin Drugs 0.000 claims description 5
- 150000001780 cephalosporins Chemical class 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- OTEANHMVDHZOPB-SLINCCQESA-M flucloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl OTEANHMVDHZOPB-SLINCCQESA-M 0.000 claims description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- RXDALBZNGVATNY-CWLIKTDRSA-N ampicillin trihydrate Chemical compound O.O.O.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 RXDALBZNGVATNY-CWLIKTDRSA-N 0.000 claims description 2
- 229960002988 benzathine cloxacillin Drugs 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229960003326 cloxacillin Drugs 0.000 claims description 2
- COCFKSXGORCFOW-VZHMHXRYSA-N cloxacillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl.N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl COCFKSXGORCFOW-VZHMHXRYSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- -1 amine salt Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 7
- 239000000404 calcium aluminium silicate Substances 0.000 description 6
- 235000012215 calcium aluminium silicate Nutrition 0.000 description 6
- WNCYAPRTYDMSFP-UHFFFAOYSA-N calcium aluminosilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O WNCYAPRTYDMSFP-UHFFFAOYSA-N 0.000 description 6
- 229940078583 calcium aluminosilicate Drugs 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229960002793 amoxicillin sodium Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VOUGEZYPVGAPBB-UHFFFAOYSA-N penicillin acid Natural products OC(=O)C=C(OC)C(=O)C(C)=C VOUGEZYPVGAPBB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 229940074415 potassium silicate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000429 sodium aluminium silicate Substances 0.000 description 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to intramammary compositions, to a process for their preparation, and to a method for their use.
- U.K. Pat. No. 1508977 describes clavulanic acid, of formula (I): ##STR1## and its salts; and the use of such compounds as synergists for penicillins and cephalosporins.
- the present invention provides an intramammary composition
- a suspension in an oily vehicle of a solid salt of clavulanic acid comprising a suspension in an oily vehicle of a solid salt of clavulanic acid; and molecular sieve powder.
- the salts of clavulanic acid used in the composition may be any of the solid salts described in U.K. Pat. No. 1508977 which are acceptable from a point of view of toxicity for intramammary administration.
- compositions of this invention are especially effective when they contain an alkali, or alkaline earth metal, or t-butylamine [NH 2 C(CH 3 ) 3 ] salt of clavulanic acid.
- the clavulanic acid salt is the sodium, potassium, calcium, magnesium or t-butylamine salt, preferably sodium or potassium.
- compositions of this invention will also contain a penicillin or cephalosporin.
- Suitable penicillins and cephalosporins for use in these compositions include any of those set out in U.K. Pat. No. 1508977, more especially those well known in the art for mastitis therapy.
- Such penicillins include sodium amoxycillin, amoxycillin trihydrate, sodium ampicillin, ampicillin trihydrate, sodium cloxacillin, benzathine cloxacillin and sodium flucloxacillin.
- compositions of this invention include sodium or potassium clavulanate; and sodium amoxycillin or amoxycillin trihydrate.
- the weight ratio (as free acids) of the penicillin or cephalosporin to the clavulanic acid salt in such compositions is suitably 5:1 to 1:1, for example about 2:1 to 3:1.
- the active ingredients (taken as free acids) will suitably represent 0.1 to 40%, more suitably 1 to 40% (w/w). Within these ranges particularly suitably values are 4 to 8%, 15 to 25% and 30 to 40%.
- Molecular sieves are commercially available in powder form. Suitable molecular sieves for our use are for example crystalline sodium, potassium or calcium alumino-silicate, preferably the calcium alumino-silicate.
- the molecular sieve powder will usually be present as 0.1 to 30%, more suitably 5 to 20% of the composition, by weight.
- the oily vehicle may be a mineral oil, or a vegetable oil such as arachis oil, sesame oil, corn oil, cottonseed oil, soyabean oil, olive oil, or fractionated coconut oil.
- compositions and the release rate of active ingredient may be varied by making an appropriate choice of oily vehicle and optional additives therefor.
- an emulsifying agent may be included in the composition to hasten the mixing of the composition with the aqueous secretions in the udder; alternatively the base described in West Germany Offenlegungsschrift No. 26 35 476 may be used, namely fractionated coconut oil (the disclosure of this Offenlegungsschrift is incorporated herein by reference).
- a more hydrophobic oil vehicle which has been more strongly gelled with a gelling agent, such as aluminium stearate, is used.
- Thickening agents such as Thixcin R and silica may also be included in the compositions if so desired, and when present will normally represent 0.1 to 8%, more suitably 1 to 5% of the composition by weight.
- compositions of the invention include those comprising a suspension in fractionated coconut oil of sodium amoxycillin or amoxycillin trihydrate; and sodium or potassium clavulanate; and molecular sieve powder; in which composition the weight ratio of amoxycillin to clavulanate salt (as free acids) is 5:1 to 1:1, the active ingredients (as free acids) represent 1 to 40% of the composition, and the molecular sieve represents 5 to 20% of the composition.
- compositions of this invention as unit doses containing a therapeutically effective amount of the chosen active ingredient.
- amoxycillin containing unit dose compositions suitably contain 100 to 1200 mg of amoxycillin (as free acid), for example 200 and 1000 mg.
- unit dose compositions suitably contain 20 to 300 mg of clavulanic acid salt (as free acid), more suitably 25 to 100 mg.
- the invention also provides a method of treatment or prophylaxis of mammary disorders in animals, which method comprises the intramammary administration of an effective amount of a composition of the invention.
- compositions will be filled into the tubes or syringe packs of the conventional type for intramammary administration, i.e. provided with a cannula nozzle for insertion into the teat to allow extrusion directly into the mammary gland via the streak canal.
- a single dose of the composition will normally contain 1 to 10 gm., preferably 3 to 8 gm., of the composition.
- composition of the invention will provide effective treatment of prophylaxis of the mammary disorder.
- lactating cow therapy it is common practice to repeat the dose at least once (preferably three times), each dosing taking place after milking.
- compositions of the invention may be prepared by mixing the active ingredient and the molecular sieve with the oily vehicle.
- This process may suitably be carried out stepwise as follows:
- This composition was prepared as follows:
- the suspension was filled as 3 gm doses into intramammary syringes.
- Triglyceride of caproic acid 3% max.
- Triglyceride of caprylic acid 50-65%
- Triglyceride of capric acid 30-45%
- Triglyceride of lauric acid 5% max.
- Thixcin R is 12-hydroxystearin.
- Molecular Sieve 5A is commercially available from Union Carbide, and is known as calcium alumino-silicate.
- This composition was prepared as follows:
- the suspension was filled as 3 gm doses into intramammary syringes.
- This composition was prepared as follows:
- the suspension was filled as 3 gm doses into intramammary syringes, (dried at 50° C. for 72 hours).
- the suspension was creamy coloured.
- Example 4 The method used was analogous to that of Example 4, resulting in a cream coloured suspension being formed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB42336/78 | 1978-10-27 | ||
| GB7842336 | 1978-10-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/345,474 Reissue USRE31301E (en) | 1978-10-27 | 1982-02-03 | Intramammary compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4282202A true US4282202A (en) | 1981-08-04 |
Family
ID=10500661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/088,859 Ceased US4282202A (en) | 1978-10-27 | 1979-10-29 | Intramammary compositions |
| US06/345,474 Expired - Lifetime USRE31301E (en) | 1978-10-27 | 1982-02-03 | Intramammary compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/345,474 Expired - Lifetime USRE31301E (en) | 1978-10-27 | 1982-02-03 | Intramammary compositions |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US4282202A (enExample) |
| EP (1) | EP0010904B1 (enExample) |
| JP (1) | JPS5559108A (enExample) |
| AU (1) | AU524193B2 (enExample) |
| CA (1) | CA1121724A (enExample) |
| DE (1) | DE2962727D1 (enExample) |
| IE (1) | IE48976B1 (enExample) |
| IL (1) | IL58461A0 (enExample) |
| NZ (1) | NZ191910A (enExample) |
| ZA (1) | ZA795679B (enExample) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537887A (en) * | 1980-09-27 | 1985-08-27 | Beecham Group Limited | Pharmaceutical formulation |
| WO2000012088A1 (en) * | 1998-08-28 | 2000-03-09 | Smithkline Beecham Plc | Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate |
| EP1044680A1 (en) * | 1999-04-13 | 2000-10-18 | Beecham Pharmaceuticals (Pte) Limited | Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US20010038838A1 (en) * | 1995-09-07 | 2001-11-08 | Smithkline Beecham Corporation | Pharmaceutical formulation |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6746692B2 (en) | 1999-04-13 | 2004-06-08 | Beecham Pharmaceuticals (Pte) Limited | Modified release pharmaceutical formulation comprising amoxycillin |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| US6783773B1 (en) | 1999-04-13 | 2004-08-31 | Beecham Pharmaceuticals (Pte) Limited | Composition comprising amoxicillin and potassium clavulanate |
| US7011849B2 (en) | 2000-10-12 | 2006-03-14 | Beecham Pharmaceuticals (Pte) Limited | Second release phase formulation |
| US20080076749A1 (en) * | 2006-09-26 | 2008-03-27 | Taro Pharmaceuticals U.S.A., Inc. | Stabilizing compositions for antibiotics and methods of use |
| US20090247575A1 (en) * | 2008-03-26 | 2009-10-01 | Taro Pharmaceuticals North America, Inc. | Stabilizing lipid compositions for oral pharmaceutical agents |
| US10828311B2 (en) | 2012-02-27 | 2020-11-10 | Bayer New Zealand Limited | Controlled release compositions and their methods of use |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3266580D1 (en) * | 1981-12-02 | 1985-10-31 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
| GB2119649B (en) * | 1982-05-12 | 1986-02-12 | Beecham Group Plc | Ophthalmic cloxacillin compositions |
| GB8629481D0 (en) * | 1986-12-10 | 1987-01-21 | Beecham Group Plc | Veterinary treatment |
| GB9007143D0 (en) * | 1990-03-30 | 1990-05-30 | Beecham Group Plc | Veterinary composition |
| US5643902A (en) * | 1990-04-26 | 1997-07-01 | Pfizer Inc. | Veterinary treatment |
| GB9009446D0 (en) * | 1990-04-26 | 1990-06-20 | Beecham Group Plc | Veterinary composition |
| SI9200139A (en) * | 1992-07-08 | 1994-03-31 | Lek Tovarna Farmacevtskih | New inclusion complex of clavulanic acid with hydrophylyc and hydropholyc beta-cyclodextrin derivates for production of them |
| DE102004021281A1 (de) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| WO2006077856A1 (ja) * | 2005-01-19 | 2006-07-27 | Nippon Zenyaku Kogyo Co., Ltd. | 乳房炎用注入剤 |
| CN101406450B (zh) * | 2007-10-12 | 2010-08-25 | 河南农业大学 | 复方阿莫西林油混悬注射液制备工艺 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914443A (en) * | 1958-03-31 | 1959-11-24 | Abbott Lab | Ointment |
| US3234028A (en) * | 1961-09-20 | 1966-02-08 | Union Carbide Corp | Process for banana ripening |
| US3250680A (en) * | 1960-07-19 | 1966-05-10 | Gillette Co | Heat-generating cosmetic composition |
| US3733403A (en) * | 1970-01-26 | 1973-05-15 | Squibb & Sons Inc | Gelled mineral oil |
| US3912806A (en) * | 1973-05-24 | 1975-10-14 | Beecham Group Ltd | Method of treating bovine mastitis |
| US3923969A (en) * | 1973-06-12 | 1975-12-02 | Battelle Institut E V | Carrier system for a drug with sustained release |
| US3998973A (en) * | 1975-04-07 | 1976-12-21 | R. T. Vanderbilt Company, Inc. | Thickening composition |
| US4000254A (en) * | 1966-04-25 | 1976-12-28 | Schmid Laboratories, Inc. | Fungimycin compositions |
| DE2635476A1 (de) * | 1975-08-14 | 1977-02-24 | Beecham Group Ltd | Tierarzneimittel und verfahren zu ihrer herstellung |
| US4064230A (en) * | 1966-04-25 | 1977-12-20 | Schmid Laboratories, Inc. | Polyenic macrolide compositions |
| US4071374A (en) * | 1975-06-23 | 1978-01-31 | Gripsin Industries, Inc. | Friction cosmetic gel |
| US4145429A (en) * | 1974-09-21 | 1979-03-20 | Beecham Group Limited | Oral veterinary preparations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3302995A (en) * | 1963-05-01 | 1967-02-07 | Thomas D Oulton | Synthetic swelling lithium aluminum silicate hydrate product |
| GB1508977A (en) * | 1974-04-20 | 1978-04-26 | Beecham Group Ltd | Beta-lactam antibiotic from streptomyces clavuligerus |
| US3996355A (en) * | 1975-01-02 | 1976-12-07 | American Home Products Corporation | Permanent suspension pharmaceutical dosage form |
| GB1561592A (en) * | 1976-05-05 | 1980-02-27 | Beecham Group Ltd | Antibacterial composition |
| JPS5325005A (en) * | 1976-08-19 | 1978-03-08 | Marutai Doboku Kk | Method of driving steellpipe pile |
| DE2654709C3 (de) * | 1976-12-02 | 1987-07-09 | A. H. Robins Co. Inc., Richmond, Va. | Verfahren zum Stabilisieren von Baldrianextraktpräparaten |
-
1979
- 1979-10-16 IL IL58461A patent/IL58461A0/xx unknown
- 1979-10-18 DE DE7979302254T patent/DE2962727D1/de not_active Expired
- 1979-10-18 EP EP79302254A patent/EP0010904B1/en not_active Expired
- 1979-10-22 AU AU52008/79A patent/AU524193B2/en not_active Expired
- 1979-10-24 NZ NZ191910A patent/NZ191910A/xx unknown
- 1979-10-24 ZA ZA00795679A patent/ZA795679B/xx unknown
- 1979-10-26 CA CA000338545A patent/CA1121724A/en not_active Expired
- 1979-10-26 JP JP13860579A patent/JPS5559108A/ja active Granted
- 1979-10-26 IE IE2061/79A patent/IE48976B1/en not_active IP Right Cessation
- 1979-10-29 US US06/088,859 patent/US4282202A/en not_active Ceased
-
1982
- 1982-02-03 US US06/345,474 patent/USRE31301E/en not_active Expired - Lifetime
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914443A (en) * | 1958-03-31 | 1959-11-24 | Abbott Lab | Ointment |
| US3250680A (en) * | 1960-07-19 | 1966-05-10 | Gillette Co | Heat-generating cosmetic composition |
| US3234028A (en) * | 1961-09-20 | 1966-02-08 | Union Carbide Corp | Process for banana ripening |
| US4000254A (en) * | 1966-04-25 | 1976-12-28 | Schmid Laboratories, Inc. | Fungimycin compositions |
| US4064230A (en) * | 1966-04-25 | 1977-12-20 | Schmid Laboratories, Inc. | Polyenic macrolide compositions |
| US3733403A (en) * | 1970-01-26 | 1973-05-15 | Squibb & Sons Inc | Gelled mineral oil |
| US3912806A (en) * | 1973-05-24 | 1975-10-14 | Beecham Group Ltd | Method of treating bovine mastitis |
| US3923969A (en) * | 1973-06-12 | 1975-12-02 | Battelle Institut E V | Carrier system for a drug with sustained release |
| US4145429A (en) * | 1974-09-21 | 1979-03-20 | Beecham Group Limited | Oral veterinary preparations |
| US3998973A (en) * | 1975-04-07 | 1976-12-21 | R. T. Vanderbilt Company, Inc. | Thickening composition |
| US4071374A (en) * | 1975-06-23 | 1978-01-31 | Gripsin Industries, Inc. | Friction cosmetic gel |
| DE2635476A1 (de) * | 1975-08-14 | 1977-02-24 | Beecham Group Ltd | Tierarzneimittel und verfahren zu ihrer herstellung |
Non-Patent Citations (2)
| Title |
|---|
| Chemical Abstracts 73:48542m (1970) Czech Patent 132,788 6/15/69. * |
| Chemical Abstracts 74:33288f (1971) [Malkin, L. et al. Khim. Tekhnd. Topl. Masel (1970) 15(9), 22-3]. * |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537887A (en) * | 1980-09-27 | 1985-08-27 | Beecham Group Limited | Pharmaceutical formulation |
| US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| US20010038838A1 (en) * | 1995-09-07 | 2001-11-08 | Smithkline Beecham Corporation | Pharmaceutical formulation |
| US6726908B2 (en) | 1995-09-07 | 2004-04-27 | Smithkline Beecham P.L.C. | Pharmaceutical formulation |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| WO2000012088A1 (en) * | 1998-08-28 | 2000-03-09 | Smithkline Beecham Plc | Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate |
| US6746692B2 (en) | 1999-04-13 | 2004-06-08 | Beecham Pharmaceuticals (Pte) Limited | Modified release pharmaceutical formulation comprising amoxycillin |
| US20040241227A1 (en) * | 1999-04-13 | 2004-12-02 | Beecham Pharmaceutials (Pte) Limited | Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan |
| BE1013309A5 (fr) * | 1999-04-13 | 2001-11-06 | Beecham Pharm Pte Ltd | Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium. |
| GR1003560B (el) * | 1999-04-13 | 2001-03-16 | Beecham Pharmaceuticals (Pte) Limited | Σκευασματα τροποποιημενης απελευθερωσης αμοξυκιλλινης και κλαβουλανικου καλιου |
| JP2002541187A (ja) * | 1999-04-13 | 2002-12-03 | ビーチャム・ファーマシューティカルズ・（プライベイト）・リミテッド | 新規治療法 |
| NL1014915C2 (nl) * | 1999-04-13 | 2001-02-12 | Beecham Pharm Pte Ltd | Nieuwe behandelingsmethode. |
| WO2000061116A3 (en) * | 1999-04-13 | 2001-02-01 | Beecham Pharm Pte Ltd | Pharmaceutical formulation comprising amoxycillin and clavulanate |
| US6660299B2 (en) | 1999-04-13 | 2003-12-09 | Beecham Pharmaceuticals Limited | Modified release pharmaceutical formulation comprising amoxycillin |
| US20040067925A1 (en) * | 1999-04-13 | 2004-04-08 | Beecham Pharmaceuticals (Pte) Limited | Novel method of treatment |
| FR2792198A1 (fr) * | 1999-04-13 | 2000-10-20 | Beecham Pharm Pte Ltd | Formulations pharmaceutiques nouvelles comprenant de l'amoxycilline et du clavulanate de potassium |
| EP1044680A1 (en) * | 1999-04-13 | 2000-10-18 | Beecham Pharmaceuticals (Pte) Limited | Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate |
| JP4880125B2 (ja) * | 1999-04-13 | 2012-02-22 | ビーチャム・ファーマシューティカルズ・（プライベイト）・リミテッド | 新規治療法 |
| US6783773B1 (en) | 1999-04-13 | 2004-08-31 | Beecham Pharmaceuticals (Pte) Limited | Composition comprising amoxicillin and potassium clavulanate |
| US6294199B1 (en) | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
| US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
| CN100382782C (zh) * | 1999-04-13 | 2008-04-23 | 比彻姆药品(Pte)有限公司 | 一种释放改良型药用制剂 |
| US7217430B2 (en) | 1999-04-13 | 2007-05-15 | Beecham Pharmaceuticals (Pte) Limited | Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan |
| US7250176B1 (en) | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
| US7011849B2 (en) | 2000-10-12 | 2006-03-14 | Beecham Pharmaceuticals (Pte) Limited | Second release phase formulation |
| US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
| US20080076749A1 (en) * | 2006-09-26 | 2008-03-27 | Taro Pharmaceuticals U.S.A., Inc. | Stabilizing compositions for antibiotics and methods of use |
| WO2008039472A3 (en) * | 2006-09-26 | 2008-11-27 | Taro Pharmaceuticals Usa Inc | Stabilizing compositions for antibiotics and methods of use |
| US8106040B2 (en) | 2006-09-26 | 2012-01-31 | Taro Pharmaceuticals North America, Inc. | Stabilizing compositions for antibiotics and methods of use |
| US8461143B2 (en) | 2006-09-26 | 2013-06-11 | Taro Pharmaceuticals North America, Inc. | Stabilizing compositions for antibiotics and methods of use |
| CN101516334B (zh) * | 2006-09-26 | 2013-07-10 | 塔罗制药北美有限公司 | 用于抗生素的稳定组合物以及应用方法 |
| US20090247575A1 (en) * | 2008-03-26 | 2009-10-01 | Taro Pharmaceuticals North America, Inc. | Stabilizing lipid compositions for oral pharmaceutical agents |
| US10828311B2 (en) | 2012-02-27 | 2020-11-10 | Bayer New Zealand Limited | Controlled release compositions and their methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5559108A (en) | 1980-05-02 |
| EP0010904B1 (en) | 1982-05-05 |
| ZA795679B (en) | 1980-10-29 |
| CA1121724A (en) | 1982-04-13 |
| EP0010904A3 (en) | 1980-07-23 |
| AU524193B2 (en) | 1982-09-02 |
| JPH0223530B2 (enExample) | 1990-05-24 |
| AU5200879A (en) | 1980-05-01 |
| USRE31301E (en) | 1983-07-05 |
| IE48976B1 (en) | 1985-06-26 |
| EP0010904A2 (en) | 1980-05-14 |
| DE2962727D1 (en) | 1982-06-24 |
| IL58461A0 (en) | 1980-01-31 |
| NZ191910A (en) | 1982-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4282202A (en) | Intramammary compositions | |
| US4401674A (en) | Intramammary compositions | |
| US5114929A (en) | Pharmaceutical formulation | |
| CA1070615A (en) | Veterinary compositions of semi-synthetic penicillin | |
| US3912806A (en) | Method of treating bovine mastitis | |
| CA1326998C (en) | Veterinary treatment | |
| US3639560A (en) | Veterinary treatment | |
| WO2003063877A1 (en) | Cefquinome composition for intra-mammary administration in cattle | |
| US5395622A (en) | Calcium chloride containing preparation for the prevention or the treatment of hypocalcemia in ruminants | |
| US4145429A (en) | Oral veterinary preparations | |
| US4029782A (en) | Cefazolin suspension for parenteral administration | |
| CA1336411C (en) | Veterinary composition containing cloxacillin | |
| CA2081348C (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
| EP0193283A1 (en) | Thiazoloquinoline derivatives, process for their preparation and compositions containing them | |
| US5643902A (en) | Veterinary treatment | |
| JPS60169431A (ja) | β−ラクタム環を有する化合物を含有する安定な抗菌剤及びその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |